comprehensive -WSS

comprehensive

author：hotspot 2025-09-30 00:47:11 - browse：3

Biogen announced a new round of cost cuts Tuesday, saying that it plans to save $700 million in operating costs and cut 1,000 jobs by 2025.

The company also released second quarter sales and earnings that handily topped the forecasts of Wall Street analysts. In early morning trading, Biogen shares rose more than 1%.

Biogen is attempting to recover from a series of corporate stumbles, the biggest of which involved the development and launch of the Alzheimer’s drug Aduhelm. The medicine was the first of a new class of disease-modifying Alzheimer’s drugs to be approved by the Food and Drug Administration. But doubts about the quality of the data behind the medicine meant that Medicare wouldn’t pay for it and doctors did not prescribe it. The resulting financial disaster cleaned out Biogen’s executive suite.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Coloradans with cystic fibrosis could lose access to Trikafta

WSS

Sarepta Duchenne therapy fails to meet primary endpoint in trial

What the cancer research community can learn from the Covid response

White House drug shortage group privately met with industry

Readout LOUD podcast: ESMO highlights & Roivant's big deal

OTC birth control: A brief history of over the counter pill design

Bill would allow buprenorphine prescription for addiction via telehealth

Wikipedia

comprehensive

focus

New air purifier tech could be key to improving indoor air quality

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Apple is now the first public company to be valued at $3 trillion

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Hollywood unions extend contract negotiations for actors

What is microchimerism and how does it affect maternal health?

Medicare details structure of new drug price negotiation program

Prime Medicine says its gene editing passes test in monkeys

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

After Sarepta trial failure, Duchenne families brace for more debate

entertainment

The health care issue Democrats can’t solve: hospital reform

My superpower is killing ticks

Key Senate panel to consider PBM, drug pricing reform package

How neuroscience research could help beat back brain cancer

Influencer to be charged after chaos erupts in New York City's Union Square

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

explore

Wikipedia

hotspot

leisure time